LIXTE Biotechnology Attending the DealFlow Discovery Conference, January 28-29

BOCA RATON, Fla., Jan. 20, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), a clinical-stage pharmaceutical company advancing LB-100, a first-in-class inhibitor of protein phosphatase 2A (PP2A), today announced the Company will participate at the DealFlow Discovery Conference in Atlantic City, New Jersey, January 28-29, 2026. Geordan Pursglove, LIXTE’s Chief Executive Officer, will conduct one-on-one meetings with investors during the conference.

The conference will be held at The Borgata Hotel, Casino & Spa, 1 Borgata Way. To register or schedule a one-on-one meeting, please visit https://dealflowdiscoveryconference.com/registration/

About LIXTE Biotechnology Holdings, Inc.

LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. LIXTE has demonstrated that its first-in-class lead clinical PP2A inhibitor, LB-100, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data (see www.lixte.com), LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer.

LIXTE’s lead compound, LB-100, is part of a pioneering effort in an entirely new field of cancer biology – activation lethality – that is advancing a new treatment paradigm. LIXTE's new approach is covered by a comprehensive patent portfolio. Proof-of-concept clinical trials are currently in progress for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer and Advanced Soft Tissue Sarcoma. Additional information about LIXTE can be found at www.lixte.com.

Through LIXTE’s wholly owned subsidiary, Liora Technologies Europe Ltd., the Company also is pioneering the development of electronically controlled proton therapy systems for treating tumors in various types of cancers. Liora’s proprietary flagship technology, LiGHT System, is believed to provide significant advantages over currently available technologies for treating tumors with proton therapy. Additional information about Liora Technologies can be found at www.lioratechnologies.com.

For more information about LIXTE, contact: 

[email protected]
General Phone: (631) 830-7092; Investor Phone: (888) 289-5533
or
PondelWilkinson Inc. Investor Relations [email protected]
Roger Pondel: (310) 279-5965; Laurie Berman: (310) 279-5962

You May Also Be Interested In

• Ackermans & van Haaren publishes convening notice for the Extraordinary Shareholder Meeting of October 15, 2026
• Breaking into the Global Top Three for Premium Displays, Chinese Smartphone Brand iQOO Set to Unveil a Breakthrough Display Product
• How to Prepare for US Debt Default: A Practical Guide to Protecting Against U.S. National Debt Risks Released by IRAEmpire